Attenuating Muscle Mass Loss in Critical Illness: the Role of Nutrition and Exercise

Lee-anne S. Chapple 1,2,3 • Selina M. Parry 4 • Stefan J. Schaller 5,6

Abstract

Purpose of Review Impaired recovery following an intensive care unit (ICU) admission is thought related to muscle wasting. Nutrition and physical activity are considered potential avenues to attenuate muscle wasting. The aim of this review was to present evidence for these interventions in attenuating muscle loss or improving strength and function.

Recent Findings Randomised controlled trials on the impact of nutrition or physical activity interventions in critically ill adult patients on muscle mass, strength or function are presented. No nutrition intervention has shown an effect on strength or function, and the effect on muscle mass is conflicting. RCTs on the effect of physical activity demonstrate conflicting results; yet, there is a signal for improved strength and function with higher levels of physical activity, particularly when commenced early.

Summary Further research is needed to elucidate the impact of nutrition and physical activity on muscle mass, strength and function, particularly in combination.

Keywords Muscle mass • Intensive care • Recovery • Nutrition • Physical activity

Introduction

Muscle Loss in Critical Illness

Recovery from Critical Illness

Critically ill patients are the sickest in the hospital, requiring substantial medical intervention for organ support. It has been reported that 20–70% of critically ill patients have low muscle mass at baseline [1], and ICU survivorship is affected by acute and extensive muscle wasting, with up to 30% lost within the first week of an ICU admission [2••]. This muscle wasting has consequences for patient recovery, with functional disability observed in ICU survivors even five years after ICU discharge [3], leading to an increase in healthcare utilisation, delayed capacity to engage in the workforce and ultimately a loss of independence [4•, 5•]. The ability to prevent or reverse skeletal muscle loss in critically ill patients is considered paramount to recovery.

Reasons for Muscle Loss in ICU

The mechanisms behind the observed loss in muscle mass, strength and physical functioning are complex, likely
multifactorial and still being elucidated [6]. Maintaining muscle mass is dependent on a tightly regulated equilibrium between muscle protein synthesis and muscle protein breakdown, an equilibrium that is impaired in critical illness [7]. Whilst studies of whole-body protein turnover in critical illness have shown an increase in whole-body protein synthesis when compared to healthy volunteers, this does not compensate for the higher rate of protein breakdown also observed [8•]. This catabolic state is the result of significant systemic changes, which occur at muscle, nerve, immune, metabolic and mitochondrial levels exacerbated by periods of immobility and nutrient deficits [6, 9]. In addition, critically ill patients have been shown to experience anabolic resistance, with a blunted capacity to utilise dietary protein for muscle protein synthesis [10••], and extended periods of inactivity impact on the bioenergetic level, affecting the force production capability of muscles to recover [6, 9].

Measuring Muscle Mass, Strength and Function in Critical Illness

The measurement of skeletal muscle mass, strength and function in critical illness is met with a number of logistical challenges. Assessment of strength and function within ICU is limited by the large proportion of critically ill patients that are unable to follow commands required for active participation as a result of being intubated and ventilated or factors like delirium or fatigue in awake patients. These measures are therefore more often conducted at a later stage of the ICU/hospital admission. Given lower muscle mass and poorer muscle quality (echogenicity) have been shown to correlate with reduced strength and function [6, 11], muscle mass is frequently used as a surrogate measure that can be conducted at the bedside to measure the acute response to an intervention. Gold standard methodologies for measuring muscle mass such as dual-energy x-ray absorptiometry (DXA) or magnetic resonance imaging (MRI) are rarely feasible as patients are often too unstable to be transferred out of the ICU to undergo such measurements alongside the additional considerations of costs and radiation exposure [12]. Historically, measures of nutritional statuses, such as mid-arm muscle circumference and proved popular, though they are affected by fluid shifts in ICU [13]. More recently, the assessment of muscularity using measures of psoas muscle from computed tomography (CT) scans of the third lumbar region collected for clinical purposes have been used [14]. This technique is equally limited in application due to radiation, preventing its implementation into clinical practice. Furthermore, a range of bedside noninvasive clinical methods has been introduced into ICU to quantify muscle size including ultrasonography [15, 16] and bio-electrical impedance [17].

Strategies to Attenuate Muscle Loss or Improve Strength or Function

Skeletal muscle is highly responsive to external stimuli such as nutrition and physical activity interventions [7]. In health, a number of nutritional strategies have been shown effective in stimulating muscle protein synthesis, including essential amino acids or their metabolites (such as leucine and HMB) [18] and higher protein doses [19]. Physical activity and dietary intake are modifiable factors associated with the risk of chronic morbidity and mortality in the general population and can positively impact on muscle mass [20, 21]. Further gains in muscle mass and strength can be induced through structured exercise such as resistance training which is needed to ‘load’ the muscle and induce a training effect [9, 22]. Accordingly, general physical activity guidelines recommend a minimum of 30 min moderate-intensity aerobic exercise on five days per week combined with at least two sessions of moderate-intensity resistance training, particularly in the older and co-morbid population [23]. Nutrition and physical activity in combination may also confer greater benefits for muscle mass, strength and function than either intervention in isolation. Participation in exercise without the availability of amino acids results in rates of muscle protein breakdown that exceed rates of muscle protein synthesis leading to muscle loss [24]. Furthermore, muscle protein synthesis following amino acid provision is greater when combined with exercise than in the rested state due to an increase in both the magnitude and duration of muscle protein synthesis [25].

As ICU survivorship has improved, attention has shifted to potential strategies to improve recovery for critically ill patients. These often focus on attenuating muscle mass loss in the acute phase of illness with the aim of improving strength and function at a later time point. Given this, there has been a paradigm shift towards prioritising both nutrition and exercise interventions as part of usual ICU care practices, as reflected within recent clinical guidelines [26••, 27–29, 30••]. Consequently, there has been an exponential increase in the number of studies conducted in this important area. In this review, we discuss how nutrition and physical activity interventions may be employed in critical illness to attenuate muscle mass loss and improve strength and physical function. For the purpose of this review, we have focused on interventions commencing within the ICU setting.

Nutrition and Physical Activity in Critical Illness

Defining Nutrition in the ICU Setting

Critically ill patients are frequently unable to consume nutrients orally due to the need for tracheal intubation. Therefore,
critical care nutrition guidelines recommend the provision of liquid nutrition via a feeding tube into the stomach—termed enteral nutrition (EN) [28, 29]. Critical care nutrition is a relatively new field of research, with a shift over the last 10 years from small physiological studies to robust large clinical trials [31]. The delivery of adequate nutrition to critically ill patients is challenging, frequently limited by extended periods of fasting and barriers to delivery caused by insulin resistance and gastrointestinal dysfunction [32, 33]. Given this, the evidence base for nutrition recommendations, particularly those on outcomes of muscle mass, strength and function, is limited.

**Defining and Measuring Physical Activity and Exercise in the ICU Setting**

Physical activity is defined as ‘any bodily movement produced by skeletal muscles that results in energy expenditure’ [34]. This encompasses all movement which may occur as part of leisure time, work or daily activities. Exercise is often used interchangeably with physical activity; however, it is important to note that exercise is a subset of physical activity [34]. Exercise is defined as ‘planned, structured, a repetitive bodily movement where the purpose is to improve or maintain physical fitness’ [34]. Physical activity and exercise can be quantified in terms of the FITT principles: frequency (i.e. how often), intensity (i.e. how hard), time (i.e. duration of individual session and overall programme length) and type of modality (i.e. cycle ergometry, functional mobility). The health benefits of regular participation in physical activity are well documented within the literature with guidelines existing for the general, older and chronic disease populations [35, 36].

Metabolic equivalent of tasks (METs) is a simple way of expressing the energy cost or intensity of physical activity [35]. The resting metabolic state is defined as one MET and refers to the amount of oxygen consumed at rest. The intensity of physical activity can be defined as low (<3.0 METs), moderate (3–5.9 METs) and vigorous (>6 METs) [35]. Within the ICU setting, patients are profoundly inactive which is in part due to the impact of their severity of illness, physiological instability, sedation, delirium and concomitant ICU life-saving treatments received [37]. External factors include ICU and hospital room designs that do not encourage awake patients to be mobile and a lack of physical therapists or nurses to perform mobilisation [38]. There is significant heterogeneity in the energy costs associated with physical activity in the ICU setting. Beach et al. demonstrated that some participants recorded high physical activity levels in terms of MET levels (measured using the Sensewear armband mini-fly motor sensor) even whilst sedated and not participating in rehabilitation activities. Most of these patients were septic, which can result in a hypermetabolic state and thus altered MET levels [39]. Black et al. assessed the oxygen costs associated with exercise interventions in mechanically ventilated ICU patients. There was significant variability in the oxygen costs of exercise between participants, which may have been influenced by factors such as the ability to actively contribute to exercise, and found that the recovery time for ~25% of sessions was longer than the total exercise duration [40]. Dysfunctional mitochondrial functioning and regeneration capacity/production of ATP which is necessary for muscle contraction has been recognised within the ICU population [9]. More work needs to be undertaken to understand the bioenergetic costs of different types of physical activity (both in bed and out of bed) and the interplay with altered/dysfunctional mitochondrial functioning.

**Nutrition for Attenuation of Muscle Mass, Strength and Function in Critical Illness**

A total of 12 RCTs of nutrition interventions in critical illness, of which two were pilot RCTs, were identified that included an outcome of muscle mass, strength or function (Table 1). Of these, the majority were conducted in Australia (n = 5) or Europe (n = 4). The interventions tested were primarily a strategy to increase nutrition overall (including calorie and protein delivery) (n = 7), protein delivery alone (n = 3) or the addition of a nutritional compound (e.g. HMB; n = 2). Six of the identified studies used a parenteral component to achieve greater nutrition delivery, either parenteral nutrition or intravenous amino acids alone [42–44, 46, 50, 52]. Seven studies reported an outcome related to muscle mass (including CT or ultrasound-derived muscle thickness or cross-sectional area (CSA)) [45–47, 48, 49, 50, 51], three relating to strength (handgrip strength) [46, 50, 52] and six studies relating to function (including Barthel Index, 6-min walk test and SF-36 physical component summary score) [41–44, 50, 52].

In 119 patients, Ferrie et al. delivered augmented protein intravenously compared to standard care and reported an attenuation of ultrasound-derived muscle layer thickness at day 7 with the greater protein dose (control: 2.8±0.4 vs intervention: 3.2±0.4 cm; p < 0.0001). This difference, however, was not sustained to ICU discharge [46]. Similarly, Fetterplace et al. compared augmented calorie and protein delivery to standard care in 60 patients, reporting greater amelioration of ultrasound-derived quadriceps muscle layer thickness (QMLT) loss with the intervention (mean difference (95% CI) 0.22 (0.06–0.38) cm, p = 0.01) [47]. These results are conflicting with more recent investigations. In 2021, Dresen et al. reported no difference in ultrasound-derived QMLT from study inclusion to week 2 or 4 with a higher protein dose (1.8 vs 1.2 g/kg/day [45]); however, this study recruited patients after an extended duration of ICU stay (day 13±2 of ICU admission), and hence, the window of intervention success may have passed by this point (given muscle loss occurs early).
| Author, year, country | Population | Intervention | Control | Muscle mass, strength or functional outcome | Summary of results |
|----------------------|------------|--------------|---------|-------------------------------------------|-------------------|
| Allingstrup, 2017, Denmark [41] | 199 pts, MV, expected to stay >3d in ICU | Early goal-directed nutrition (based on indirect calorimetry and 24-h urinary urea) | Standard care (25 kcal/kg/day via EN) | Primary: SF-36 PCS score at 6 months | No difference in SF-36 PCS score between groups, mean, control vs intervention: 23 vs 22.9, diff (95% CI) 0.0 (−5.9−5.8), p = 0.99; data available for n = 88 vs 88 pts |
| Casaer, 2011, Belgium [42] | 4640 pts, at nutritional risk (NRS ≥ 3) | Early PN (by day 3) | Delayed PN (by day 8) | Secondary: 6MWT iADLs | No difference in SF-36 physical function, mean±SD: control vs intervention: 40.7 ±29.6 vs 42.5±30.8, diff (95% CI) 1.8 (1.85−5.52), p = 0.33; data available for n = 513 vs 524 pts |
| Doig, 2013, Australia [43] | 1372 pts, contraindications to early EN, expected to stay in ICU >2 d | Early PN | Standard care | Secondary: D60 SF-36 physical function | No difference in SF-36 physical function, mean±SD: control vs intervention: 40.7 ±29.6 vs 42.5±30.8, diff (95% CI) 1.8 (1.85−5.52), p = 0.33; data available for n = 513 vs 524 pts |
| Doig, 2015, Australia [44] | 474 pts, expected to stay in ICU >2 d | Early PN | Standard care | Secondary: D90 SF-36 general health status and physical function | No difference in SF-36 General Health, mean±SD: control vs intervention: 52.8±25.9 vs 50.5±27.2, diff (95% CI) 2.3 (−3.1−7.7), p = 0.41; data available for n = 180 vs 192 pts |
| Dresen, 2021, Germany [45*] | 42 pts, MV, haemodynamically stable, expected to require >28 d organ support | 1.8 g protein/kg/day | 1.2 g protein/kg/day | Primary: change in ultrasound-derived QMLT from study inclusion to weeks 2 and 4 | No difference in muscle loss between groups; change in mean QMLT, control vs intervention: −0.28±0.08 vs −0.15±0.08 mm; p=0.368 |
| Ferrie, 2016, Australia [46] | 119 pts, receiving PN, expected to receive ≥3 d of the intervention | 1.2 g/kg IV amino acid supplementation | Standard care | Secondary: ultrasound-derived muscle thickness of quadriceps, forearm and mid-upper arm at D7 | No difference in handgrip strength, mean±SD, control vs intervention: 15.8±10.4 vs 18.5±10.4 cm; p = 0.054 |
| Fetterplace, 2018, Australia [47] | 60 pts, MV ≤48 h, anticipated to remain MV ≥72 h | Volume-based EN with protein supplementation | Usual care (continuous hourly rate EN) | Secondary: change in ultrasound-derived QMLT from ICU admission to discharge | Greater ultrasound-derived forearm muscle thickness at D7 with intervention, mean ±SD, control vs intervention: 2.8±0.4 vs 3.2±0.4 cm; p < 0.0001 |
| McNelly, 2020, UK [48*] | 121 pts, expected MV ≥48 h, requiring gastric EN, multiorgan failure, likely ICU stay ≥7 d and likely survival ≥10 d | Intermittent EN | Continuous EN | Primary: change in ultrasound-derived RF-CSA over 10 days | No difference in RF-CSA, mean±SD, control vs intervention: −19.8±14.2 vs −17.4±14.6 cm, diff (95% CI) −2.4 (−9.7−4.8), p = 0.505 |
| Author, year, country | Population | Intervention | Control | Muscle mass, strength or functional outcome | Summary of results |
|-----------------------|------------|--------------|---------|-------------------------------------------|---------------------|
| Nakamura, 2020, Japan [49] | 50 pts, receiving EN, haemodynamically stable | Standard EN + 3 g HMB, 14 g arginine, 14 g glutamine | Standard EN | Primary: rate of CT-derived femoral muscle volume loss from day 1 to 10 | Change to day 10; mean difference (95% CI): $-1.1 (-6.1-4.0); p = 0.676$ |
| Ridley, 2018, Australia [50] | 100 pts, ≥16 y, adm to ICU in previous 48–72 h, receiving MV and expected to continue until day after randomisation, central venous access, ≥1 defined organ system failure | Supplemental PN | Standard care | Secondary: ICU mobility scale (or 6MWT where possible) at hospital discharge | No difference in ICU mobility scale, median (IQR), control vs intervention: 8 [4–10] vs 9 [5–10], $p = 0.58$; data available for $n = 33$ vs 25 pts |
| Viana, 2021, Switzerland [51] | 30 pts, MV, likely survival ≥7 d | HMB | Placebo (maltodextrin) | Primary: magnitude of loss of ultrasound-derived quadriceps muscle CSA from day 4 to 15 | No difference in handgrip strength, mean±SD, control vs intervention: 20±13 vs 19±13.5 kg, $p = 0.71$; data available for $n=24$ vs 19 pts |
| Wischmeyer, 2017, USA Pilot RCT [52] | 125 pts, acute respiratory failure, expected to require MV >72, BMI <25 or ≥35 | Standard EN + supplemental PN | Standard EN | Secondary: Barthel Index at hospital discharge | No difference in muscle loss between groups; mean skeletal muscle area (control D1 114 (95% CI 43–185.8) to D14 100.4 (95% CI 32.6–168.2) cm$^2$ vs intervention D1 110.5 (95% CI 43.7–177.2) to D14 99.3 (95% CI 25.7–172.92) cm$^2$, $p = 0.86$ |

*6MWT, 6-minute walk test; BMI, body mass index; CSA, cross-sectional area; CT, computed tomography; EN, enteral nutrition; D, day; HGS, handgrip strength; HMB, B-hydroxy-B-methylbutyrate; iADLs, independent with activities of daily living; IV, intravenous; MV, mechanical ventilation; PCS, physical component summary; PN, parenteral nutrition; QMLT, quadriceps muscle layer thickness; RCT, randomised controlled trial; SF-36, Short Form 36*
[53]. Furthermore, McNelly et al. found no difference in the attenuation of rectus femoris CSA over 10 days with greater calorie/protein delivery with intermittent feeding (daily protein dose: intermittent: 63.8 (59.3–68.3) g vs control: 55.8 (49.1–62.5) g; p = 0.048) [48•]. Two RCTs have reported no effect on muscle mass with an intervention containing hydroxymethylbutyrate (HMB), a metabolite of leucine known to stimulate muscle protein synthesis and reduce muscle protein breakdown in health: Nakamura et al. reported no effect of a combined HMB/arginine/glutamine intervention on CT-derived femoral muscle volume loss [49•] and Viana et al. reported no difference in magnitude of the loss of ultrasound-derived quadriceps muscle CSA from day 4 to 15 [51•]. Reasons for these discrepancies in results are unclear but may be related to the timing of intervention (early versus late protein delivery) or the type of protein delivered (specific versus mixed amino acids).

No study of a nutrition intervention has been shown to be effective in improving any outcome of strength or function in critically ill patients.

Physical Activity for Attenuation of Muscle Mass, Strength and Function in Critical Illness

Exercise interventions have been shown to be safe and feasible within the ICU setting and fall into three main modalities: neuromuscular electrical stimulation (which involves artificial stimulation of the underlying muscles with surface electrodes), assistive technology such as cycle ergometry (with/without additional muscle stimulation) and functional-based strengthening and mobility training. For the purposes of this review, we have focused our reporting on cycle ergometry and functional-based mobility interventions. Recent systematic reviews have demonstrated exercise commencing in the ICU (such as mobilisation functional-based exercises) improves physical functioning at hospital discharge and reduces ICU and hospital length of stay and may improve mobility status and reduce the incidence of ICU-related weakness, muscle strength and days alive [54••, 55, 56].

A total of 28 RCTs of cycling/functional mobility in critical illness, of which three were pilot RCTs, were identified that included an outcome of muscle mass, strength or function (Tables 2 and 3). Of these, 79% of the studies were from Europe (n = 8), Australia (n = 6) or North/South America (n = 8). There is significant heterogeneity in terms of the modalities, frequency, timing and intensity of programmes which make it challenging to compare. This is in addition to varying trial endpoints and many lacking follow-ups beyond hospital discharge.

Exercise can be considered a drug as it causes a range of beneficial effects for health, as do pharmacological interventions [85]. Drug trials adhere to rigorous testing processes to determine the minimum effective dose, with titration up to a maximum dose level beyond which the adverse effects of the drug outweigh the benefits. Exercise trials have traditionally not undergone the same scrutiny as drug trials. Currently, the exercise dose that a patient receives is poorly described and articulated within ICU trials. This is in part due to the lack of consistency in defining the ‘dosage’ of interventions and reporting of the actual versus planned intervention delivery. Recently within the stroke literature, a dose articulation framework has been developed to improve the rigour in exercise dosage reporting which is also applicable to the ICU setting [86•]. Scheffenbichler et al. used a Mobilisation Quantification Score to address the problem of dose [87•]. Within exercise dosage, we need comprehensive reporting of what is planned and then what was delivered with consideration of the FITT principles: frequency, intensity, time (individual session duration and overall programme length) and type of activities (including individual tasks, task duration) [86•].

Timing and Duration of Intervention

It appears that the greatest benefit may be observed in trials commencing within the first 72 hours of ICU admission with trials demonstrating higher muscle strength, functional independence, higher level of mobility including distance able to be walked and earlier attainment of mobility milestones at hospital discharge (Table 3). It also appears that rehabilitation delivered less than 5 days per week may be less effective [55, 79••, 88]. The length of the ICU-based exercise programmes may be another confounder. Numerous trials have had a median of 3–7 sessions delivered (often over 7–10 days) which may be too short an intervention period to induce changes in muscle mass, strength and function.

Frequency/Intensity

Achievement of higher levels of mobility has been related to better physical recovery outcomes for ICU survivors [70, 79••, 87•, 89•]. Conflicting evidence exists with regards to the increasing frequency of sessions, with several studies demonstrating 2× sessions per day resulted in earlier attainment of mobility milestones and improved strength [66, 68, 69, 73, 84]. This contrasts with a recently published secondary analysis of a prospective study of 186 ICU patients which found that increasing the number of mobility sessions did not independently influence health status 6 months post-ICU admission. It is important to note that there was variability in the amount of active mobilisation sessions performed in ICU, with 19% of the cohort performing less than one session per week and just under half completing a mobility session every 1–3 days with less than 5% completing more than one session per day. More research is required to elucidate the prescription
| Author, year, country | Population | Timing | Intervention | Comparator | Muscle mass, strength or functional outcome | Results |
|------------------------|------------|--------|--------------|------------|--------------------------------------------|---------|
| Berney, 2021, Australia [57] | 162 ICU patients with sepsis or systemic inflammatory response syndrome ≥48 h MV and ICU LOS ≥4 d | <72 h | 60 min FES cycling ≥5 days/week until ICU discharge; single leg allocation FES cycling and other leg without FES | Usual care (respiratory and functional mobility) | Primary: quadriceps strength Second: MRC-SS handgrip strength PFIT-s FSS-ICU SPPB 6MWT Katz ADL RF-CSA | Primary: no significant difference between groups for quadriceps strength at hospital discharge Secondary: no significant difference between groups for any secondary measures |
| Burtin, 2009, Belgium [58••] | 90 S/MICU patients with predicted ICU LOS >7 d | Late (>5 d after ICU admission) | Cycle ergometry 5 days/week 20 min per session individually adjusted intensity Passive 20 cycles/min or active 2× 10 min bouts increasing intensity until hospital discharge | Usual care (respiratory physiotherapy + standardised mobility of UL and LL 5 days per week) ranging from passive to active depending on the capability | Primary: 6MWD Second: quadriceps strength Handgrip strength Berg Balance Scale FAC SF-36 (PF domain) | Primary outcome: higher 6MWD distance in intervention at hospital discharge (196 vs 143 m, p < 0.05) Secondary: quadriceps strength gain higher between ICU discharge and hospital discharge in intervention (p < 0.01); no significant difference between groups for handgrip strength; Berg Balance Scale and FAC at ICU and hospital discharge; higher SF-36 (PF domain) scores in the intervention group at hospital discharge (21 vs 15 points, p < 0.01) |
| Eggmann, 2018, Switzerland [59] | Mixed MV ICU patients with ICU LOS ≥72 h | <48 h | 5× week (with weekends as clinically indicated) up to a maximum of 3 sessions per day, endurance cycling (20 min/d at pedalling rate of 20 cycles/min) up to a max of 60 min at full resistance; resistance training for UL and LL (active assisted, weighted), 8–12 reps with 2–5 sets at 5–80% of estimated 1RM max, functional mobility tasks | Usual care (early mobility, respiratory therapy and passive/active exercises) | Primary: 6MWD and FIM Second: quadriceps strength Handgrip strength MRC-SS FIM TUG test SF-36 | Primary: no significant difference between groups for 6MWD and FIM at hospital discharge Secondary: no significant difference in secondary outcomes |
| Fossat, 2018, France [60] | 314 ICU patients admitted to ICU <72 h before randomisation | <48 h | 1× 15 min session of cycling, 1× 50 min session/day of EMS of bilateral quads, 5× week until ICU discharge | Usual care | Primary: MRC-SS Secondary: ICU Mobility Scale Katz ADL Barthel Index SF-36 RF-CSA | No significant difference between groups in MRC-SS at ICU discharge Secondary: no significant difference between groups for any secondary measures |
| Gama Lordello, 2020, Portugal [56] | 234 ICU cardiac surgery patients | Within 6–8 h | 2× day until ICU discharge Cycle ergometry active 10 min (5 min LL, 5 min UL) | 2× day 10 min of active exercises for LL and UL repeated 10× | Primary: in-hospital steps per day | No significant difference between groups for steps per day over three days following allocated intervention |
| Author, year, country | Population | Timing | Intervention | Comparator | Muscle mass, strength or functional outcome | Results |
|-----------------------|------------|--------|--------------|------------|--------------------------------------------|---------|
| Brazil [61]           | following extubation | 66 ICU <4 d of MV and <7 d ICU LOS | 5 sessions per week of 30 min passive, to active cycling until ICU discharge + usual care | Secondary: no difference in steps per day between groups |
| Kho, 2019, Canada [62] | <72 h | 38 MV ICU patients with acute respiratory failure | Median 2 d | No difference between groups for PFIT-s scores at hospital discharge |
| Machado, 2017, Brazil [63] | <96 h | 72 mixed ICU patients expected to MV >48 h | 30 min daily in bed cycling 1× day (up to 6 days per week) | Primary: no significant between group differences in muscle atrophy of RF-CSA at day 10 |

ADL, activities of daily living; CSA, cross-sectional area; FAC, functional ambulation category; FES, functional electrical stimulation; FIM, functional independence measure; FSS-ICU, functional status score in the ICU; ICU, intensive care unit; LL, lower limb; LOS, length of stay; min, minutes; MICU, medical ICU; MRC-SS, Medical Research Council sum score; MV, mechanical ventilation; PA, physical activity; PFIT-s, Physical Function in ICU test scored; RF, rectus femoris; SICU, Surgical ICU; SF-36, Short Form 36 Questionnaire; SFBB, Short Physical Performance Battery; TUG test, timed up and go test; UL, upper limb; VI, vastus intermedius; HRM max, one repetition maximum; 6MWT, six-minute walk test; 6MWD, six-minute walk distance; %, percentage
| Author, year, country | Population | Timing | Intervention | Comparator | Muscle mass, strength or functional outcome | Results |
|------------------------|------------|--------|--------------|------------|---------------------------------------------|---------|
| Cui, 2020, China [65]  | 178 off-pump CABG patients aged 60 years or above | <48 h  | Precision early ambulation duration and intensity determined by age-predicted maximal heart rate and VO2Max. Day 1: 10 min sitting Day 2: SOOB >10 min, standing 3-5 min; walking 20m Day 3: SOOB >10 min, standing 5 min and walk minimum of 30 m. Exercises repeated up to 5 times per day | Routine ambulation – patients engaged in ambulation on day 2 or 3 after surgery | Ambulation outcome reported (but not a pre-specified primary or secondary endpoint) | Significant difference between groups for ambulation distance on day 3 (75 m vs 56 m, p < 0.001) |
| Dantas, 2012, Brazil [66] | 59 ICU MV patients | Unclear (however, patients excluded if MV >7 d) | 2× day, 7 times per week at a moderate intensity level in ICU | Conventional physical therapy – passive mobility of UL, LL 5× week and active assisted exercises depending on the capability | MRC-SS | Significant improvement in muscle strength over the duration of the intervention (p = 0.00) – however, higher baseline MRC-SS scores compared to control |
| Denehy, 2013, Australia [67] | 150 mixed ICU patients ICU LOS >5 d | Late >5 d  | Functional mobility and strengthening exercises, aerobic training beginning in ICU and continuing for 8 weeks post-hospital discharge (up to an hour) at moderate intensity | Usual care (respiratory and mobility in hospital), no outpatient service | Primary: 6MWD Secondary: TUG test SF-36 AQOL | No significant difference for 6MWD between groups at 6 months, exploratory analyses demonstrated the rate of change over time and mean between group differences in 6MWD from the first assessment greater in the intervention group NB: did not reach enrolment target of 200 Secondary: no difference between groups for secondary outcomes |
| Dong, 2014, China [68] | 60 ICU patients with tracheal intubation or tracheostomy 48–72 h with predicted MV >7 d | 48–72 h | 2× day daily until hospital discharge, functional mobility tasks | Control group (unspecified) | Time to first sit out of bed in days | Faster to sit out of bed in the intervention (mean of 3.8 vs 7.3 days; p = 0.00) |
| Hickmann, 2018, Belgium [69] | 19 ICU patients with septic shock | <48 h  | 2× 30 min session/daily for one week with 1 session of functional mobility and 1×30 min passive/active cycling | Usual care (5× week, functional mobility) | Primary: regulation of protein degradation/synthesis pathways during the first week Secondary: muscle fibre CSA Exercise-induced muscle inflammation | Primary: reduced protein degradation in the intervention group but no significant difference between groups over the first week Secondary: muscle fibre CSA preserved by exercise between days 1 and 7 (~26% in control vs 12.4% in intervention, p = 0.005); no significant difference between groups for exercise-induced inflammation |

<72 h | Usual care |
| Author, year, country | Population | Timing | Intervention | Comparator | Muscle mass, strength or functional outcome | Results |
|-----------------------|------------|--------|--------------|------------|--------------------------------------------|---------|
| Hodgson, 2016, Australia Pilot RCT [70] | 50 mixed ICU patients MV >48 h | Active exercises for 1 hour per day, early goal-directed mobility focused on functional mobility | Primary: higher maximal level and duration of activity measured using IMS Scale Secondary: PFIT-s FSS-ICU MRC-SS IADL | Higher levels of activity (mean IMS 7.3 vs 5.9; p = 0.05) and duration of activity in intervention (median 20 vs 7 min; p = 0.002) Secondary: no significant differences between groups for secondary measures |
| Hodgson, 2020, Australia Pilot RCT [71] | 20 ICU ECMO patients | Early goal-directed mobility | Usual care (respiratory and functional mobility) | Primary: higher duration of mobility in the intervention (median 133 vs 27.5 min) but no difference between groups for IMS maximal score (2.67 vs 1.5 points) Secondary: between group difference in favour of early goal-directed mobility group for Katz ADL (functional independence at hospital discharge) |
| Kayambu, 2015, Australia Pilot RCT [72] | 50 mixed CU patients with sepsis syndromes, MV >48 h | 1–2 × 30 min sessions/day until ICU discharge involving EMS, functional mobility and cycling | Usual care (respiratory and functional mobility) | No difference between groups in ACIF scores at ICU discharge |
| Mafiet, 2017, France [73] | 40 ICU liver transplant recipients | 2× day early progressive rehabilitation involving P/AROM, functional mobility until ICU discharge | Usual care (referral to physiotherapy with 1 session per day) | Time to first mobility milestones (sitting on the edge of the bed, sitting in the chair and walking) No significant difference between groups for time to first sit in a chair or walking Median time to the first mobilisation was significantly shorter in the intervention group (8 vs 10 days, p = 0.055) and a higher level of mobility on Manchester Mobility Score at ICU discharge (MMS 7 vs 5, p = 0.016) |
| McWilliams, 2018, UK Pilot RCT [74] | 103 ICU patients MV ≥5 d | Enhanced rehabilitation | Usual care | | |
| Morris, 2016, USA [75] | 300 MICU patients requiring noninvasive or invasive MV | Standardised rehabilitation therapy involving PROM, PT and progressive resistance training, 3× sessions per day, seven days per week until hospital discharge | Usual care | Primary: no significant difference between groups for hospital LOS Secondary: no difference between groups for secondary outcomes except SPPB, where there was a significantly higher score for SPPB, SF-36 (PF domain) and FPI score at 6 months within the intervention group |
| Moss, 2016, USA [76] | 120 MV (≥4 d) MICU patients | Intensive rehab for 28 days (7× week in hospital and 1× week outpatient/home) | Usual care (3× week focused on ROM, positioning and | Primary: no significant difference between groups for Continuous Scale Physical |
| Author, year, country | Population | Timing | Intervention | Comparator | Muscle mass, strength or functional outcome | Results |
|----------------------|------------|--------|--------------|------------|---------------------------------------------|---------|
| Nava, 1998, Italy [77] | 80 RICU COPD patients | Unspecified commenced in RICU | 2× 30–45 min sessions daily of comprehensive rehab involving Steps 1 and 2: P/AROM, respiratory Rx, mobility training; step 3: respiratory muscle training 2× 10 min, cycling 1× 20 min at a workload of 15 watts and flight of 25 stairs 5×; step IV: 3 weeks 2× 30 min treadmill walking at 70% pre-exercise test score | Control group (steps 1 and 2 only) | Functional Performance Test Secondary: 5 times sit to stand TUG test Berg Balance Scale SF-36 | 6MWD Significant improvement in 6MWD in intervention group at hospital discharge (< 0.0001) |
| Nydahl, 2020, Germany [78] | Cluster randomised pilot study | Median 3 d | Intervention period: goal-directed mobility plan based on ICU Mobility Scale and interprofessional rounds daily | Control period: usual care | Primary: percentage of patients with ICU Mobility Score of 3 or more | Primary: non statistically significant increase in out-of-bed mobility by 9.6% |
| Schaller, 2016, Germany [79] | 200 SICU patients MV <48 h and expected further MV >24 h | <48 h | Early goal-directed mobility involving daily morning ward round to set mobility goal and second goal implementation cross shifts with interprofessional communication follow-up | Usual care | Primary: SOMS level Secondary: modified FIM MRC-SS SF-36 | Primary: significant differences between groups in favour of intervention for mean SOMS score Secondary: significant differences between groups for modified FIM at hospital discharge in favour of intervention; no difference between groups for MRC-SS or SF-36. |
| Schweickert, 2009, USA [80] | 104 pts | <48 h | Passive ROM for all limbs (10 repetitions), transitioned to active assisted and active ROM exercises, bed mobility and sitting and ADL/exercise, walking, daily basis until returned to the previous level of function or discharged from hospital | Usual care | Primary: functional independence Secondary: Barthel Index Number of functionally independent ADLs Distance walked without assistance MRC-SS Handgrip strength | Primary: greater functional independence at hospital discharge in the intervention group (59 vs 35 %, p = 0.02) with the faster achievement of mobility milestones (i.e. sitting, standing, marching and walking) in favour of the intervention group (p > 0.0001), a greater walking distance at hospital discharge Secondary: Higher Barthel Scores, a higher number of independent ADLs and greater unassisted walking distance in the intervention group at hospital discharge; |
| Author, year, country | Population | Timing | Intervention | Comparator | Muscle mass, strength or functional outcome | Results |
|-----------------------|------------|--------|--------------|------------|-------------------------------------------|---------|
| Seo, 2019, Korea [81] | 16 ICU patients in ICU ≥5d | >5 d | Exercise group included P/AROM, resistance training, functional mobility | Cycle ergometry 5x week for 30 min until ICU discharge | MRC-SS, FSS-ICU, SF-36 | There was a significant difference between groups for MRC-SS and handgrip strength at hospital discharge |
| Schujmann, 2020, Brazil [82] | 99 ICU patients scoring 100 or above on Barthel Index 2 weeks prior to ICU admission | <48 h | Combined therapy consisting of a combination of conventional therapy and a programme of early and progressive mobility, 2x day 5x week, duration ~40 min | Conventional therapy involving active assists and active mobilisation as well as bed positioning, bedside and armchair transfers and ambulation. 2x day, 5x week | Primary: Barthel Index, Secondary: handgrip strength, EMG of anterior tibial, medial gastroc and VL muscles. TUG test, Sit to stand test, 2-min walk test, Physical activity levels | Higher Barthel Scores for intervention at ICU discharge (97 vs 76, p < 0.001). No differences between groups for grip strength, EMG or TUG test. Difference between groups observed for sit to stand (8 vs 5 repetitions, p < 0.01), 2-min walk test (p < 0.001) and ICU Mobility Score at ICU discharge (9.8 vs 7, p < 0.001). Higher levels of physical activity in the intervention (1539 steps/day vs 591 in control, p < 0.001). |
| Wright, 2017, UK [83*] | 308 ICU MV ≥48 h <72 h | 90 min rehab 5x week until ICU discharge split across 2 sessions until ICU discharge | 30 min rehab 5x week | Primary: SF-36 (PF domain), Secondary: modified Rivermead Mobility Index, 6MWT, FIM | No significant difference between groups for SF-36 (PF) and modified Rivermead Mobility Index. Higher levels of physical activity in the intervention compared to usual care (1539 steps/day vs 591 in control, p < 0.001). |
| Yosef Brauner, 2015, Israel [84] | 18 ICU MV ≥48 h and expected to remain ventilated for further 48 h | Conventional physiotherapy (more intensive 2x day) involving respiratory and functional elements – respiratory, P/AROM, functional mobility | Conventional physiotherapy MRC-SS Handgrip strength Sitting balance | There was a significant difference in the intensive treatment group over time compared to usual care for MRC-SS (p = 0.029) and non-significant for handgrip and sitting balance. |

ADL, activities of daily living; AQOL, Assessment of Quality of Life Questionnaire; AROM, active range of motion; CSA, cross-sectional area; ECMO, extracorporeal membrane oxygenation; EMS, electrical muscle stimulation; FIM, Functional Independence Measure; FPI, Functional Performance Inventory; HHD, handheld dynamometry; IADL, instrumented activities of daily living; ICU, intensive care unit; IMS, ICU Mobility Scale; LOS, length of stay; LL, lower limb; MICU, medical ICU; min, minutes; MRC-SS, Medical Research Council sum score; MV, mechanical ventilation; PFIT-s, Physical Function in ICU test scored; PROM, passive range of motion; PT, physiotherapy; Rx, treatment; SF-36, Short Form 36 Questionnaire; SOM, Surgical Optimal Mobility Scale; SPPB, short physical performance battery; TUG test, timed up and go test; UL, upper limb; 6MWD, six-minute walk distance; %, percentage
parameters in terms of intensity, frequency and duration which may result in the greatest long-term benefits for ICU patients [61, 89•]. Several trials have attempted to provide higher programme intensities but failed to implement these targets [59, 83•]. The discrepancy between planned and actual therapy delivery in these trials has occurred due to patient- and setting-related barriers (e.g. participant fatigue, sedation) [59, 83•] as well as logistic challenges with missed physiotherapy visits due to weekends, medical procedures and/or physiological instability [59, 83•]. It may be that the field has overestimated how much patients may be able to achieve in the early ICU period, as it is likely that the muscle fatigue threshold required for a training response is lower in critical illness, particularly in the context of impaired muscle/nerve functioning [54••]. More work needs to be undertaken to understand the impact of fatigued and to develop personalised approaches to prescribing exercise doses within the ICU population.

**Exercise Mode**

Functional-based movement is the most used exercise intervention within the ICU setting and often involves sitting, standing, walking and resistance-based exercises (Table 3). The importance of goal-directed early mobility has been emphasised in recent trials in terms of interprofessional communication and optimising patient status (in terms of sedation, pain, delirium) to achieve a target mobility level [70, 79•••]. Several studies have proven that mobility can improve strength and physical functioning and impact on other important outcomes such as delirium and length of stay. There has been growing interest in the last 10 years in non-volitional exercise interventions which may enable earlier targeted optimisation of muscle mass and strength due to the awareness of muscle wasting occurring early and rapidly and the delay until patients are alert and able to engage in functional-based exercises [90]. Electrical muscle stimulation which involves artificial stimulation of the muscle using transcutaneous electrodes placed over the skin is one promising modality [56]. There is conflicting evidence; however, some studies have demonstrated the preservation of muscle mass and strength within the ICU setting [91•, 92]. The optimal stimulation parameters and impact on long-term outcomes need to be determined as well as the patient subgroups who may be of most benefit. Cycle ergometry is another attractive intervention which can be utilised passively (without patient effort whilst in a coma) and actively with increasing resistance. Burtin et al. conducted the first RCT of cycle ergometry compared to usual care in the ICU which found significant improvements in exercise capacity as measured by the six-minute walk distance (196 vs 143 m, p < 0.05), and quadriceps force improved more between ICU and hospital discharge in the treatment group (1.83 vs 2.37 N/kg (intervention), 1.86 vs 2.03 N/kg, p < 0.01) [58••]. Subsequent cycle trials have found conflicting results with heterogeneity in outcomes measured, timing of intervention and dosage parameters used, making it difficult to make comparisons [59–64] (Table 2).

**Nutrition and Physical Activity – a Combined Intervention?**

As we understand that the combination of amino acid administration and exercise has a synergistic effect on stimulating muscle protein synthesis in health [24, 25], we also need to understand the mutual benefit of combined interventions of nutrition and exercise which may augment gains in muscle mass, strength and physical functioning in critical illness. Only two RCTs in critical illness have been published that explore the combination of nutrition and physical activity interventions on outcomes of muscle mass, strength or function (Table 4). De Azevedo et al. randomised 181 patients to receive either nutrition guided by indirect calorimetry with augmented protein delivery (including via supplemental parenteral nutrition) and twice daily cycle ergometry exercise or standard care, reporting improved function at 3 months and 6 months with the intervention when using the SF-36 Physical Component Summary score, but no difference in handgrip strength between groups [94••]. Zhou et al. randomised 150 patients into one of three study arms: standard care versus early mobilisation versus early mobilisation plus early nutrition (within 48 hours of ICU admission) [93••]. They reported reduced ICU-acquired weakness and improved functional status using Barthel Index with both interventions compared to standard care.

**Future Directions**

As this research field advances, we will continue to see a greater focus on combined exercise and nutrition therapies, with a number of clinical trials registered on this topic [95]. The ICU population is a highly heterogeneous population in terms of admission diagnoses and comorbid health statuses. Pre-ICU health factors such as comorbidities, age, sex and baseline nutritional status are likely to impact the response to exercise and nutrition, as well as the post-ICU recovery trajectory [96]. Therefore, a personalised approach to nutrition and exercise delivery may be needed with the identification of subgroups who may respond to different therapies and dosage levels. Greater articulation of the planned intervention delivery and actual delivery against intervention reporting frameworks are required. The separation between intervention and usual care also needs to be clearly documented, particularly as usual care nutrition delivery and mobility practices continue to evolve.
### Table 4  Summary of randomised controlled trials of combined nutrition and physical activity interventions on muscle mass, strength or function

| Author, year, country | Population | Timing | Intervention | Comparator | Muscle mass, strength or functional outcome | Results |
|-----------------------|------------|--------|--------------|------------|---------------------------------------------|---------|
| Zhou, 2022, China [93**] | 150 pts, adm to ICU for the first time, expected ICU stay ≥72 h, conscious enough to respond (n = 50 pts per group) | <24 h | 2 intervention arms: EM: early mobilisation (20-30 min 2×/day within 24 h) EMN: early mobilisation as per EM group + early nutrition (within 48 h of ICU adm) | Standard care: routine rehabilitation exercise and nutrition support | Primary: ICU-AW (MRC sum score <48) at ICU discharge Secondary: muscle strength from MRC sum score Barthel Index | Lower rates of ICU-AW in intervention groups, mean (95% CI), control vs intervention: 16 (7.2–29) % vs EM: 2 (0.1–10.6) % vs EMN: 2 (0.1–10.6) %; p = 0.005 MRC sum score did not differ between groups, mean (95% CI), control vs intervention: 60 (56.5–60) % vs EM: 60 (59.8–60) % vs EMN: 60 (60–60) %; p = 0.225 Improved Barthel Index with interventions mean (95% CI), control vs intervention: 57.5 (38.8–70) % vs EM: 70 (50–81.3) % vs EMN: 70 (55–80) %; p = 0.008 |
| De Azevedo, 2021, Brazil [94**] | 181 pts, MV, expected ICU stay >3 d | Nutrition guided by indirect calorimetry + high protein intake (including supp PN), cycle ergometry exercise 2×/d | Routine physiotherapy, standard nutrition provision | Primary: SF-36 PCS at 3 months and 6 months Secondary: ICU-AW defined by HGS ICU discharge | Better SF-36 PCS at 3 months with the intervention, median (IQR), control vs intervention: 0.00 (0.00–37.0) vs 24.4 (0.00–49.12); p = 0.01 Better SF-36 PCS at 6 months with the intervention, median (IQR), control vs intervention: 0.00 (0.00–55.1) vs 33.63 (0.00–71.61); p = 0.01 No difference in HGS ICU-AW, n (%), control vs intervention: 26 (46.4%) vs 16 (28.5%); p = 0.05 |
A wide range of outcome measures relating to muscle mass, strength and function are currently reported in RCTs of nutrition and physical activity interventions, restricting synthesis and interpretation of results. Core outcome sets have been published for long-term ICU recovery follow-up [97, 98] and are being developed for physical rehabilitation [99] and nutrition fields [100], which need to be adopted in order to improve comparability across future trials.

Further work is also likely to focus on the post-ICU phase, on the premise that nutrition and physical activity interventions of a sustained duration, throughout the hospital admission, are likely to be required. Whilst observational data report suboptimal nutrition intake [101, 102] and reduced physical activity [37, 39, 103] in ICU survivors, studies conducted throughout the hospital admission are lacking.

Conclusions

Overall, few studies have quantified the effect of a nutrition intervention on muscle mass, strength or function in critical illness, and both the intervention and the outcome technique used vary greatly, limiting interpretation. Few studies have quantified the role of nutrition on muscle mass, strength or function, with conflicting results, particularly in relation to the role of augmented protein dose on attenuation of muscle mass loss. The time at which physical activity interventions are commenced appears to be important, with the greatest benefit seen when intervening within the first 72 hours and ensuring a sufficient intensity of exercise. However, more work needs to be undertaken to articulate the exercise dose considerations and identify the responders who may benefit from different types of personalised approaches to optimising physical activity levels to preserve muscle mass and strength and optimising physical functioning.

Author Contribution All authors contributed to the study’s conception and design; formal analysis and investigation were performed by Lee-anne S Chapple and Selina M Parry; the original draft preparation was conducted by Lee-anne S Chapple and Selina M Parry; and review and editing of the manuscript was performed by Stefan J Schaller.

Funding Open Access funding enabled and organized by CAUL and its Member Institutions

Declarations

Conflict of Interest The authors declare no competing interests.

Human and Animal Rights and Informed Consent This article does not contain any studies with human or animal subjects performed by any of the authors.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

Papers of particular interest, published recently, have been highlighted as:

• Of importance

•• Of major importance

1. Moisey LL, Mourtzakis M, Cotton BA, Premji T, Heyland DK, Wade CE, et al. Skeletal muscle predicts ventilator-free days, ICU-free days, and mortality in elderly ICU patients. Critical Care (London, England). 2013;17(5):R206.

2. •• Puthucheary ZA, Rawal J, McPhail M, Connolly B, Ratnayake G, Chan P, et al. Acute skeletal muscle wasting in critical illness. JAMA. 2013;310(15):1591–60

Landmark paper which identified acute muscle wasting occurs early and rapidly in critical illness.

3. Herridge MS, Cheung AM, Tansey CM, Matte-Martyn A, Diaz-Granados N, Al-Saadi F, et al. One-year outcomes in survivors of the acute respiratory distress syndrome. N Engl J Med. 2003;348:683–93.

4. • Deane AM, Little L, Bellomo R, Chapman MJ, Davies AR, Ferrie S, et al. Outcomes six months after delivering 100% or 70% of enteral calorie requirements during critical illness (TARGET). A randomized controlled trial. Am J Respir Crit Care Med. 2020;201(7):814–2.

Outcome data from critically ill patients randomised to receive augmented enteral calories compared to standard care demonstrated no impact of calorie delivery on quality of life or functional outcomes.

5. • Parry SM, Nalamalapu SR, Nunna K, Rabice A, Friedman LA, Colantuoni E, et al. Six-minute walk distance after critical illness: a systematic review and meta-analysis. J Intensive Care Med. 2021;36(3):343–51

Systematic review synthesising physical functioning data measured using 6-minute walk distance with identified risk factors for poor physical functioning recovery which may be relevant to the design of clinical studies.

6. Batt J, Herridge MS, Dos Santos CC. From skeletal muscle weakness to functional outcomes following critical illness: a translational biology perspective. Thorax. 2019;74(11):1091–8.

7. Parry SM, Puthucheary ZA. The impact of extended bed rest on the musculoskeletal system in the critical care environment. Extrem Physiol Med. 2015;4:16.

8. • Liebau F, Deane AM, Rooyackers O. Protein absorption and kinetics in critical illness. Curr Opin Clin Nutr Metab Care. 2021;24(1):71–

A broad review on impairments in protein metabolism in critically ill patients.

9. Bear DE, Parry SM, Puthucheary ZA. Can the critically ill patient generate sufficient energy to facilitate exercise in the ICU? Curr Opin Clin Nutr Metab Care. 2018;21(2):110–5.
10. •• Chapple LS, Kouw IWK, Summers MJ, Weinel LM, Gluck S, Raith E, et al. Muscle protein synthesis following protein administration in critical illness. Am J Respir Crit Care Med. 2022. https://doi.org/10.1164/rccm.202112-2780OC Using comprehensive tracer methodology, this study reported skeletal muscle protein synthesis following intraduodenally delivered dietary protein is impaired in critical illness, despite near normal protein digestion and amino acid absorption.

11. Hayashi I, Tamotto Y, Takahashi Y, Kusabiraki T, Tamaki J. Correlation between muscle strength and muscle mass, and their association with walking speed, in community-dwelling elderly Japanese individuals. PLoS One. 2014;9(11):e111810.

12. Looijaard WG, Dekker IM, Stapel SN, Girbes AR, Twisk JW, Oudemans-van Straaten HM, et al. Skeletal muscle quality as assessed by CT-derived skeletal muscle density is associated with 6-month mortality in mechanically ventilated critically ill patients. Crit Care. 2016;20(1):386.

13. Oikawa SY, Holloway TM, Phillips SM. The impact of step refeeding on lean body mass in critical illness. Curr Opin Crit Care. 2018;24(4):241–7.

14. Ismael S, Savalle M, Travin C, Gillaizeau F, D’Auzac C, Faisy C. The consequences of sudden fluid shifts on body composition in critically ill patients. Crit Care. 2014;18(2):R49.

15. Looijaard WG, Dekker IM, Stapel SN, Girbes AR, Twisk JW, Oudemans-van Straaten HM, et al. Skeletal muscle protein synthesis following intraduodenally delivered dietary protein is impaired in critical illness, despite near normal protein digestion and amino acid absorption.

16. Klawitter F, Walter U, Patejdl R, Endler J, Reuter DA, Ehler J. Increased rates of muscle protein turnover and amino acid translocation are observed in critically ill patients. Crit Care Med. 2017;45(10):1981–2000.

17. Klawitter F, Walter U, Patejdl R, Endler J, Reuter DA, Ehler J. Anabolic signaling deficits underlie amino acid resistance and wasting, aging muscle. FASEB J. 2005;19(3):422–3.

18. Chapple LS, Ridley EJ, Chapman MJ. Trial design in critical care nutrition: the past, present and future. Nutrients. 2020;12(12):3694.

19. Oikawa SY, Holloway TM, Phillips SM. The impact of step refeeding on lean body mass in critical illness. Curr Opin Crit Care. 2018;24(4):241–7.

20. Klawitter F, Walter U, Patejdl R, Endler J, Reuter DA, Ehler J. Anabolic signaling deficits underlie amino acid resistance and wasting, aging muscle. FASEB J. 2005;19(3):422–3.

21. Chapple LS, Ridley EJ, Chapman MJ. Trial design in critical care nutrition: the past, present and future. Nutrients. 2020;12(12):3694.

22. Oikawa SY, Holloway TM, Phillips SM. The impact of step refeeding on lean body mass in critical illness. Curr Opin Crit Care. 2018;24(4):241–7.

23. Klawitter F, Walter U, Patejdl R, Endler J, Reuter DA, Ehler J. Anabolic signaling deficits underlie amino acid resistance and wasting, aging muscle. FASEB J. 2005;19(3):422–3.

24. Chapple LS, Ridley EJ, Chapman MJ. Trial design in critical care nutrition: the past, present and future. Nutrients. 2020;12(12):3694.

25. Klawitter F, Walter U, Patejdl R, Endler J, Reuter DA, Ehler J. Anabolic signaling deficits underlie amino acid resistance and wasting, aging muscle. FASEB J. 2005;19(3):422–3.

26. Chapple LS, Ridley EJ, Chapman MJ. Trial design in critical care nutrition: the past, present and future. Nutrients. 2020;12(12):3694.
the intensive care unit and functional outcomes: an observational study. J Crit Care. 2017;40:189–96.
40. Black C, Grocott M, Singer M. The oxygen cost of rehabilitation interventions in mechanically ventilated patients: an observational study. Physiotherapy. 2020;107:169–7
This study provides important data on the oxygen cost associated with rehabilitation interventions in the ICU population.
41. Allingstrup MJ, Kondrup J, Wiis J, Claudius C, Pedersen UG, Vejborg L, et al. Early parenteral nutrition versus standard of care in adult intensive care patients: the single-centre, randomised, outcome assessor-blinded EAT-ICU trial. Intensive Care Med. 2017;43(11):1637–47.
42. Casaer MP, Mesotten D, Hermans G, Wouters PJ, Schetz M, Meyfroidt G, et al. Early versus late parenteral nutrition in critically ill adults. N Engl J Med. 2011;365(6):506–17.
43. Doig GS, Simpson F, Sweetman EA, Finfer SR, Cooper DJ, Heighes PT, et al. Early parenteral nutrition in critically ill patients with short-term relative contraindications to early enteral nutrition: a randomized controlled trial. JAMA. 2013;309(20):2130–8.
44. Doig GS, Simpson F, Bellomo R, Heighes PT, Sweetman EA, Cheshier D, et al. Intravenous amino acid therapy for kidney function in critically ill patients: a randomized controlled trial. Intensive Care Med. 2015;41(7):197–208.
45. Dresen E, Weissbrich C, Fimmers R, Putensen C, Stehle P. Medical high-protein nutrition therapy and loss of muscle mass in adult ICU patients: a randomized controlled trial. Clin Nutr. 2021;40(4):1562–70 The delivery of 1.2 g protein/kg/day versus 1.8 g protein/kg/day in critically ill patients had no impact on ultrasound-derived muscle loss.
46. Ferrie S, Allman-Farinelli M, Finfer SR, Cooper DJ, Heighes PT, et al. Parenteral nutrition in critically ill patients: a randomized controlled trial. J PEN J Parenter Enteral Nutr. 2018;42(1):207–12.
47. Fletterplace K, Deane AM, Tierney A, Beach LJ, Knight LD, Presneill J, et al. Targeted full energy and protein delivery in critically ill patients: a pilot randomized controlled trial (FEED Trial). J PEN J Parenter Enteral Nutr. 2018.
48. McNelly AS, Bear DE, Connolly BA, Arbane G, Allum L, Tarbhai A, et al. Effect of intermittent or continuous feed on muscle wasting in critical illness: a phase 2 clinical trial. Chest. 2020;158(1):183–94 An RCT on the effect of intermittent versus continuous enteral nutrition administration in critically ill patients in which greater protein dose was received in the intermittent feeding arm, with no differences in ultrasound-derived muscle size between groups.
49. Nakamura K, Kihata A, Naraba H, Kanda N, Takahashi Y, Sonoo T, et al. beta-Hydroxy-beta-methylbutyrate, arginine, and glutamine complex on muscle volume loss in critically ill patients: a randomized control trial. J PEN J Parenter Enteral Nutr. 2020;44(2):205–1
An RCT in critically ill patients reported no difference in muscle mass using computed tomography of the femoral muscle when comparing HMB with placebo.
50. Ridley EJ, Davies AR, Parke R, Bailey M, McArthur C, Gillanders L, et al. Supplemental parenteral nutrition versus usual care in critically ill adults: a pilot randomized controlled study. Crit Care. 2018;22(1):12.
51. Viana MV, Becce F, Pantet O, Schmidt S, Bagnoud G, Thaden JJ, et al. Impact of beta-hydroxy-beta-methylbutyrate (HMB) on muscle loss and protein metabolism in critically ill patients: a RCT. Clin Nutr. 2021;40(8):4878–8
A second RCT that also reported no effect of HMB on muscle loss in critically ill patients.
52. Wischmeyer PE, Hasselmann M, Kummerlen C, Kozar R, Kutsogiannis DJ, Karvellas CJ, et al. A randomized trial of supplemental parenteral nutrition in underweight and overweight critically ill patients: the TOP-UP pilot trial. Crit Care. 2017;21(1):142.
53. Gamrin-Grippenberg L, Sundstrom-Rehal M, Olsson D, Grip J, Wernerman J, Rooyackers O. An attenuated rate of leg muscle protein depletion and leg free amino acid efflux over time is seen in ICU long-stayers. Crit Care. 2018;22(1):13.
54. Wang YT, Lang JK, Haines KJ, Skinner EH, Haines TP. Physical rehabilitation in the ICU: a systematic review and meta-analysis. Crit Care Med. 2022;50(3):375–8
A detailed systematic review synthesising the current evidence on physical rehabilitation in the ICU.
55. Tipping CJ, Harrod M, Holland A, Romero L, Nisbet T, Hodgson CL. The effects of active mobilisation and rehabilitation in ICU on mortality and function: a systematic review. Intensive Care Med. 2017;43(2):171–83.
56. Waldauf P, Jiroutková K, Krajčová A, Puthucheary Z, Duska F. Effects of rehabilitation interventions on clinical outcomes in critically ill patients: systematic review and meta-analysis of randomized controlled trials. Crit Care Med. 2020;48(7):1055–65.
57. Berney S, Hopkins RO, Rose JW, Koopman R, Puthucheary Z, Pastva A, et al. Functional electrical stimulation in-bed cycle ergometry in mechanically ventilated patients: a multicentre randomised controlled trial. Thorax. 2021;76(7):653–60.
58. Burtin C, Clerckx B, Robbeets C, Ferdinand P, Langer D, Troosters T, et al. Early exercise in critically ill patients enhances short-term functional recovery. Crit Care Med. 2009;37(9):2499–505 Outstanding trial which was the first to demonstrate the efficacy of cycle ergometry in the ICU population on short-term benefits (up to hospital discharge).
59. Eggmann S, Verra ML, Luder G, Takula J, Jakob SM. Effects of early, combined endurance and resistance training in mechanically ventilated, critically ill patients: a randomised controlled trial. PLoS One. 2018;13(11):e0207428.
60. Fossat G, Baudin F, Courtes L, Bobet S, Dupont A, Bretagnol A, et al. Effect of in-bed leg cycling and electrical stimulation of the quadriceps on global muscle strength in critically ill adults: a randomized clinical trial. JAMA. 2018;320(4):368–78.
61. Gama Lordeiro GG, Goncalves Gama GG, Gago Rosier G, Viana P, Correia LC, Fonteles Ritt LE. Effects of cycle ergometer use in early mobilization following cardiac surgery: a randomized controlled trial. Clin Rehabil. 2020;34(4):450–9.
62. Kho ME, Molloy AJ, Clarke FJ, Reid JC, Herridge MS, Karachi T, et al. Multicentre pilot randomised clinical trial of early in-bed cycle ergometry with ventilated patients. BMJ Open Respir Res. 2019;6(1):e000383.
63. Machado ADS, Pires-Neto RC, Carvalho MTX, Soares JC, Cardoso DM, Albuquerque IM. Effects that passive cycling exercise have on muscle strength, duration of mechanical ventilation, and length of hospital stay in critically ill patients: a randomized clinical trial. J Bras Pneumol. 2017;43(2):134–9.
64. Nickels MR, Aitken LM, Barnett AG, Walsham J, King S, Gale NE, et al. Effect of in-bed cycling on acute muscle wasting in critically ill adults: a randomized clinical trial. J Crit Care. 2020;59:86–93.
65. Cui Z, Li N, Gao C, Fan Y, Zhuang X, Liu J, et al. Precision medicine and learning for muscle strength in critically ill patients. Rev Bras Ter Intensiva. 2017;24(2):173–8.
66. Denehy L, Skinner EH, Edbrook L, Haines K, Warrillow S, Hawthorne G, et al. Exercise rehabilitation for patients with critical illness: a randomized controlled trial with 12 months of follow-up. Crit Care. 2013;17(4):R156.
68. Dong ZH, Yu BX, Sun YB, Fang W, Li L. Effects of early rehabilitation therapy on patients with mechanical ventilation. World J Emerg Med. 2014;5(1):48–52.

69. Hickmann CE, Castaneres-Zapatero D, Deldicque L, Van den Bergh P, Caty G, Robert A, et al. Impact of very early physical therapy during septic shock on skeletal muscle: a randomized controlled trial. Crit Care Med. 2018;46(9):1436–43.

70. Hodgson CL, Bailey M, Bellomo R, Berney S, Buhr H, Denhey L, et al. A binational multicenter pilot feasibility randomized controlled trial of early goal-directed mobilization in the ICU. Crit Care Med. 2016;44(6):1145–52.

71. ECMO-PT Study Investigators and International ECMO Network. Early mobilisation during extracorporeal membrane oxygenation was safe and feasible: a pilot randomised controlled trial. Intensive Care Med. 2020;46(5):1057–9.

72. Kayambu G, Boots R, Paratz J. Early physical rehabilitation in intensive care patients with sepsis syndromes: a pilot randomised controlled trial. Intensive Care Med. 2015;41(5):865–74.

73. Maaffei P, Wiramus S, Bensoussan L, Bienvenu L, Haddad E, Morange S, et al. Intensive early rehabilitation in the intensive care unit for liver transplant recipients: a randomized controlled trial. Arch Phys Med Rehabil. 2017;98(8):1518–25.

74. McWilliams D, Jones C, Atkins G, Hodson J, Whitehouse T, Morris PE, Berry MJ, Files DC, Thompson JC, Hauser J, Flores L, et al. Standardized rehabilitation and hospital length of stay among patients with acute respiratory failure: a randomized clinical trial. JAMA. 2016;315(24):2694–702.

75. Moss M, Nordon-Craft A, Malone D, Van Pelt D, Frankel SK, Veenith T, et al. Earlier and enhanced rehabilitation of mechanically ventilated patients in critical care: a feasibility randomised controlled trial. J Crit Care. 2018;44:407–12.

76. Morris PE, Berry MJ, Files DC, Thompson JC, Hauser J, Flores L, et al. Standardized rehabilitation and hospital length of stay among patients with acute respiratory failure: a randomized clinical trial. JAMA. 2016;315(24):2694–702.

77. Nydahl P, Gunther U, Diers A, Hesse S, Kerschensteiner C, Nava S. Rehabilitation of patients admitted to a respiratory intensive care unit for liver transplant recipients: a randomized controlled trial. Arch Phys Med Rehabil. 2017;98(8):1518–25.

78. Mos M, Nordon-Craft A, Malone D, Van Pelt D, Frankel SK, Warner ML, et al. A randomized trial of an intensive physical therapy program for patients with acute respiratory failure. Am J Respir Crit Care Med. 2016;193(10):1101–10.

79. Nava S. Rehabilitation of patients admitted to a respiratory intensive care unit. Arch Phys Med Rehabil. 1998;79(7):849–54.

80. Nydahl P, Gunther U, Diers A, Hesse S, Kerschensteiner C, Klamann S, et al. PROtocol-based MObilization on intensive care units: stepped-wedge, cluster-randomized pilot study (Promotion). Nurs Crit Care. 2020;25(6):368–75.

81. Schacker SJ, Anstey M, Bloominator M, Edrich T, Grabitz SD, Gradwohl-Matis I, et al. Early, goal-directed mobilisation in the surgical intensive care unit: a randomised controlled trial. Lancet. 2016;388(10052):1377–88. Outstanding trial which demonstrated the importance of goal-directed mobility with a coordinated team approach to achieving mobility within the surgical ICU setting.

82. Scheweckert WD, Pohlman MC, Pohlman AS, Nigos C, Pawlik AJ, Esbrook CL, et al. Early physical and occupational therapy in mechanically ventilated, critically ill patients: a randomised controlled trial. Lancet. 2009;373(9678):1874–8.

83. Wright SE, Thomas K, Watson G, Baker C, Bryant A, Chadwick TJ, et al. Intensive versus standard physical rehabilitation therapy in the critically ill (EPICC): a multicentre, parallel-group, randomised controlled trial. Thorax. 2018;73(3):213–2.

84. Trial with important implications for the field in terms of the ability to achieve higher intensities of intervention within the ICU setting based on the challenges of intervention delivery.

85. Yosef-Brauner O, Adi N, Ben Shahar T, Yechzekel E, Carmeli E. Effect of physical therapy on muscle strength, respiratory muscles and functional parameters in patients with intensive care unit-acquired weakness. Clin Respir J. 2015;5(1):1–6.

86. Framework from stroke population on how dose articulation can be described and reported in trials.

87. Cohort multi-centre study demonstrating that a higher dose of mobilization is an independent predictor of the ability to live independently after discharge.

88. Ding N, Zhang Z, Zhang C, Yao L, Yang L, Jiang B, et al. What is the optimum time for initiation of early mobilization in mechanically ventilated patients? A network meta-analysis. PLoS One. 2019;14(10):e0223151.

89. Paton M, Lane R, Paul E, Cuthbertson GA, Hodgson CL. Mobilization during critical illness: a higher level of mobilization improves health status at 6 months, a secondary analysis of a prospective cohort study. Crit Care Med. 2021;49(9):e860–89. Cohort multi-centre study demonstrating higher levels of mobility but not increasing frequency of sessions improved health status 6 months after ICU admission.

90. Schaller SJ, Scheffenbichler FT, Bose S, Mazwi N, Waak K, Schaller SJ, et al. Effects of the level and duration of mobilization therapy in the surgical ICU on the loss of the ability to live independently: an international prospective cohort study. Crit Care Med. 2021;49(3):e247–e57.

91. Burke D, Gorman E, Stokes D, Lennon O. An evaluation of neuromuscular electrical stimulation in critical care using the ICF framework: a systematic review and meta-analysis. Clin Respir J. 2016;10(4):407–20.

92. Zhou W, Yu L, Fan Y, Shi B, Wang X, Chen T, et al. Effect of early mobilization combined with early nutrition on acquired weakness in critically ill patients (EMAS): a dual-center, randomized controlled trial. PLoS One. 2022;17(5):e0268599. An RCT of early mobilisation compared to early mobilisation and early nutrition intervention compared to usual care on ICU-acquired weakness. Both intervention groups reduced ICU-acquired weakness compared to usual care.

93. de Azvedo JRA, Lima HCM, Frotta P, Nogueira I, de Souza SC, Fernandes EAA, et al. High-protein intake and early exercise in adult intensive care patients: a prospective, randomized controlled trial to evaluate the impact on functional outcomes. BMC Anesthesiol. 2021;21(1):28. An RCT in mechanically ventilated patients which combined an augmented protein intervention with cycle ergometry compared to standard care, with improved physical function at 3 months in the intervention group.
95. Heyland DK, Day A, Clarke GJ, Hough CT, Files DC, Mourtzakis M, et al. Nutrition and exercise in critical illness trial (NEXIS trial): a protocol of a multicentred, randomised controlled trial of combined cycle ergometry and amino acid supplementation commenced early during critical illness. BMJ Open. 2019;9(7):e027893.

96. Amundadottir OR, Jonasdottir RJ, Sigvaldason K, Jonsdottir H, Moller AD, Dean E, et al. Predictive variables for poor long-term physical recovery after intensive care unit stay: an exploratory study. Acta Anaesthesiol Scand. 2020;64(10):1477–90.

97. Needham DM, Sepulveda KA, Dinglas VD, Chessare CM, Friedman LA, Bingham CO 3rd, et al. Core outcome measures for clinical research in acute respiratory failure survivors. An International Modified Delphi Consensus Study. Am J Respir Crit Care Med. 2017;196(9):1122–3

98. Delphi consensus recommendations for core outcomes in clinical research for acute respiratory failure survivors.

99. Spies CD, Krampe H, Paul N, Denke C, Kiselev J, Piper SK, et al. Instruments to measure outcomes of post-intensive care syndrome in outpatient care settings – results of an expert consensus and feasibility field test. J Intensive Care Soc. 2021;22(2):159–74.

100. Connolly B, Denehy L, Hart N, Pattison N, Williamson P, Blackwood B. Physical Rehabilitation Core Outcomes In Critical illness (PRACTICE): protocol for development of a core outcome set. Trials. 2018;19(1):294.

101. Puthucheary Z, Davies T. Core outcome measures for clinical effectiveness trials of nutritional and metabolic interventions in critical illness: an International Modified Delphi Consensus Study Evaluation (CONCISE) 2022 [Available from: https://www.comet-initiative.org/Studies/Details/1838.

102. Ridley EJ, Parke RL, Davies AR, Bailey M, Hodgson C, Deane AM, et al. What happens to nutrition intake in the post-intensive care unit hospitalization period? An observational cohort study in critically ill adults. JPEN J Parenter Enteral Nutr. 2019;43(1):88–95.

103. Gupta P, Martin JL, Needham DM, Vangala S, Colantuoni E, Kandhar BB. Use of actigraphy to characterize inactivity and activity in patients in a medical ICU. Heart Lung. 2020;49(4):398–406.

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.